Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1

Status

Terminated 2Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Lung Neoplasms 2Urinary Bladder Neoplasms 1Neoplasms 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 27Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Tetrahydrouridine × Thoracic × Clear all
NCT03233724 2023-05-31

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
9 enrolled 14 charts
GastrointestinalOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Lung Neoplasms

NCT01479348 2020-06-02

Imaging Study for FdCyd and THU Cancer Treatment

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
5 enrolled 12 charts
BreastGenitourinaryHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡